UCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global Insights finding that awareness of the drug was tracking ...

Novartis' strong drug pipeline and financials support an 11% annual return by 2027. Learn why NVS stock offers 33% return ...

In this week's InnovationRx newsletter, federal judges halt Trump's cuts to NIH research payments, rural hospitals' ongoing ...

The pharmaceutical giant said it has agreed to acquire the U.S. privately held, clinical-stage biopharmaceutical company to ...

Novartis has brought abelacimab back into the fold. Six years after spinning the asset out to form Anthos Therapeutics, ...

The Swiss pharmaceutical company has set a high bar for any potential obesity-treatment acquisition as it scans the market for deals to fill its drug pipeline and power sales growth into the 2030s, ...

CEO Vas Narasimhan told the Wall Street Journal the company is searching for next-generation obesity drug candidates, even if ...

The Swiss pharmaceutical company has set a high bar for any potential obesity-treatment acquisition as it scans the market ...

Q4 2024 Earnings Call Transcript January 31, 2025 Novartis AG beats earnings expectations. Reported EPS is $1.98, ...

The pharma major beat analysts’ expectations in the fourth quarter of 2024, despite looming competition for its top heart drug Entresto.

In a significant development, Novartis' CEO Vas Narasimhan has sounded the alarm over the United States' decision to exit the World Health Organization, raising concerns about the potential ...